Significance of the BMY/Adnexus purchase. I reread the restriction on competing products that corky posted on the yahoo board (see below) and I have a few thoughts. Based on the BMY purchase of Adnexus it would appear that they are pursing adnectin-based technology as a strategy to block the extracellular domains of receptor tyrosine kinases. I cannot find the link but I recall a presentation in which BMY/Adnexus were investigating antagonists of VEGFR, EGFR, IGFR, as well as dual targeted agents. If BMY is pursuing an adnectin-based EGFR antagonist, this would appear to violate the restriction on competing products--Could this be the reason that IMCL has 100% right to 11F8?. It would seem that after buying Adnexus, it would be redundant for BMY to partner the IMCL pipeline. As I recall, the Adnexus purchase went for ~400 million, significantly less than it would cost to purchase IMCL. Comments appreciated.
biophud
RESTRICTION ON COMPETING PRODUCTS. During the period from the date of the Commercial Agreement until September 19, 2008, the parties have agreed not to, directly or indirectly, develop or commercialize a competing product (defined as a product which has as its only mechanism of action an antagonism of the EGF receptor) in any country in the Territory. In the event that any party proposes to commercialize a competing product or purchases or otherwise takes control of a third party which has developed or commercialized a competing product, then such party must either divest the competing product within 12 months or offer the other party the right to participate in the commercialization and development of the competing product on a 50/50 basis (provided that if the
News 
Market Data 
Discover 
